MedTrace Logo

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

NCT02563925 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-08-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if the combination of tremelimumab and durvalumab with brain radiation therapy can help treat this type of breast cancer that has spread to the brain.

Conditions

Interventions

RADIATION

Brain radiotherapy or Stereotactic Radiosurgery

DRUG

Tremelimumab

DRUG

HER2 directed therapy

DRUG

Durvalumab

Sponsors & Collaborators

Principal Investigators

  • Shanu Modi, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-18
Primary Completion
2021-07-14
Completion
2021-07-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02563925 on ClinicalTrials.gov